Maze Therapeutics uses its Compass genetics platform to advance kidney and obesity drugs, with MZE829 Phase 2 data due in ...

Nucleome Therapeutics nominates first preclinical development candidate First-in-class monoclonal antibody agonist programme for inflammation resolution with broad applicability across major chronic ...

The debate between dollar-cost averaging and lump-sum investing isn’t new, but it remains one of the most misunderstood concepts in personal finance. Investors regularly choose the strategy that feels ...

Artist, inventor and anatomist Leonardo da Vinci was the definition of a Renaissance man — and scientists are aiming to ...

A new peer-reviewed paper published in The Gerontologist  provides the most comprehensive scientific response to date addressing recent critiques of the so-called “blue zones,” regions of the world ...

Developing new drugs is not for the faint-hearted. “It’s a pretty perilous journey,” says Paul Nioi, vice-president of discovery and translational research at Alnylam Pharmaceuticals. “It’s expensive ...

A new peer-reviewed paper published in The Gerontologist provides the most comprehensive scientific response to date addressing recent critiques of the so-called "blue zones," regions of the world ...

Scientists have turned to artifacts associated with Leonardo da Vinci on a quest to track down the legendary polymath’s ...

A common agricultural pesticide known as chlorpyrifos may play a substantial role in the development of Parkinson’s disease. New research from the University of California, Los Angeles, combines ...

David Harper is the CEO and founder of Bionic Turtle. He is also a published author with a popular YouTube channel on expert finance topics. Probability distributions help investors model uncertainty ...

Three retirement withdrawal strategies to consider if your goal is to maximize bequests. In our recent annual study on safe ...

Learn to apply Bayes' theorem in financial forecasting for insightful, updated predictions. Enhance decision-making with ...